Ranbaxy to Market Debiopharm's New Drug in India
Indian pharma major Ranbaxy Laboratories Limited has signed an exclusive licensing agreement with Swiss biopharmaceutical development company Debiopharm Group to// market its new gastro-enterology drug. Debiopharm's new drug Sanvar, an injectable molecule, is for treatment of acute variceal bleeding and prevention of rebleeding related to portal hypertension, Ranbaxy said in a stateme...Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
Presentation of Final Phase I Monthly Implant and Phase IIa DailyOral Results LAUSANNE, Switzerland, June 11, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions,presented final results of two Debio 9902 (formerly ZT-1) studiesfor the treatment of Alzheimer's disease (AD) at the Alzheime...Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV
A Unique Viral Kinetics Profile LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions,presented additional results of a previous phase Ib, 15 day studywith cyclophilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatitis Cvirus) co-infected patients. The data we...